id	sid	tid	token	lemma	pos
dpc-4454	1	1	dermatology	dermatology	NOUN
dpc-4454	1	2	:	:	PUNCT
dpc-4454	1	3	practical	practical	ADJ
dpc-4454	1	4	and	and	CCONJ
dpc-4454	1	5	conceptual	conceptual	ADJ
dpc-4454	1	6	research	research	NOUN
dpc-4454	1	7	letter	letter	NOUN
dpc-4454	2	1	|	|	ADV
dpc-4454	2	2	dermatol	dermatol	ADJ
dpc-4454	2	3	pract	pract	NOUN
dpc-4454	2	4	concept	concept	NOUN
dpc-4454	2	5	.	.	PUNCT
dpc-4454	3	1	2024;14(4):e2024243	2024;14(4):e2024243	NUM
dpc-4454	3	2	1	1	NUM
dpc-4454	3	3	cutaneous	cutaneous	ADJ
dpc-4454	3	4	drug	drug	NOUN
dpc-4454	3	5	reaction	reaction	NOUN
dpc-4454	3	6	due	due	ADP
dpc-4454	3	7	to	to	ADP
dpc-4454	3	8	bortezomib	bortezomib	NOUN
dpc-4454	3	9	characterized	characterize	VERB
dpc-4454	3	10	by	by	ADP
dpc-4454	3	11	erythematous	erythematous	ADJ
dpc-4454	3	12	ramified	ramified	ADJ
dpc-4454	3	13	plaques	plaque	NOUN
dpc-4454	3	14	in	in	ADP
dpc-4454	3	15	a	a	DET
dpc-4454	3	16	patient	patient	NOUN
dpc-4454	3	17	with	with	ADP
dpc-4454	3	18	multiple	multiple	ADJ
dpc-4454	3	19	myeloma	myeloma	NOUN
dpc-4454	3	20	emre	emre	PROPN
dpc-4454	3	21	güven1	güven1	PROPN
dpc-4454	3	22	,	,	PUNCT
dpc-4454	3	23	yusuf	yusuf	PROPN
dpc-4454	3	24	can	can	AUX
dpc-4454	3	25	edek1	edek1	PROPN
dpc-4454	3	26	,	,	PUNCT
dpc-4454	3	27	funda	funda	PROPN
dpc-4454	3	28	tamer1	tamer1	NOUN
dpc-4454	3	29	,	,	PUNCT
dpc-4454	3	30	özlem	özlem	PROPN
dpc-4454	3	31	erdem2	erdem2	NOUN
dpc-4454	3	32	1	1	NUM
dpc-4454	3	33	department	department	NOUN
dpc-4454	3	34	of	of	ADP
dpc-4454	3	35	dermatology	dermatology	NOUN
dpc-4454	3	36	,	,	PUNCT
dpc-4454	3	37	gazi	gazi	PROPN
dpc-4454	3	38	university	university	PROPN
dpc-4454	3	39	faculty	faculty	NOUN
dpc-4454	3	40	of	of	ADP
dpc-4454	3	41	medicine	medicine	NOUN
dpc-4454	3	42	,	,	PUNCT
dpc-4454	3	43	ankara	ankara	PROPN
dpc-4454	3	44	,	,	PUNCT
dpc-4454	3	45	turkey	turkey	PROPN
dpc-4454	3	46	2	2	NUM
dpc-4454	3	47	department	department	NOUN
dpc-4454	3	48	of	of	ADP
dpc-4454	3	49	pathology	pathology	PROPN
dpc-4454	3	50	,	,	PUNCT
dpc-4454	3	51	gazi	gazi	PROPN
dpc-4454	3	52	university	university	PROPN
dpc-4454	3	53	faculty	faculty	NOUN
dpc-4454	3	54	of	of	ADP
dpc-4454	3	55	medicine	medicine	NOUN
dpc-4454	3	56	,	,	PUNCT
dpc-4454	3	57	ankara	ankara	PROPN
dpc-4454	3	58	,	,	PUNCT
dpc-4454	3	59	turkey	turkey	PROPN
dpc-4454	3	60	key	key	ADJ
dpc-4454	3	61	words	word	NOUN
dpc-4454	3	62	:	:	PUNCT
dpc-4454	3	63	bortezomib	bortezomib	NOUN
dpc-4454	3	64	,	,	PUNCT
dpc-4454	3	65	drug	drug	NOUN
dpc-4454	3	66	reaction	reaction	NOUN
dpc-4454	3	67	citation	citation	NOUN
dpc-4454	3	68	:	:	PUNCT
dpc-4454	3	69	güven	güven	PROPN
dpc-4454	3	70	e	e	NOUN
dpc-4454	3	71	,	,	PUNCT
dpc-4454	3	72	edek	edek	NOUN
dpc-4454	3	73	yc	yc	NOUN
dpc-4454	3	74	,	,	PUNCT
dpc-4454	3	75	tamer	tame	ADJ
dpc-4454	3	76	f	f	NOUN
dpc-4454	3	77	,	,	PUNCT
dpc-4454	3	78	erdem	erdem	PROPN
dpc-4454	3	79	ö.	ö.	VERB
dpc-4454	3	80	cutaneous	cutaneous	ADJ
dpc-4454	3	81	drug	drug	NOUN
dpc-4454	3	82	reaction	reaction	NOUN
dpc-4454	3	83	due	due	ADP
dpc-4454	3	84	to	to	ADP
dpc-4454	3	85	bortezomib	bortezomib	NOUN
dpc-4454	3	86	characterized	characterize	VERB
dpc-4454	3	87	by	by	ADP
dpc-4454	3	88	erythematous	erythematous	ADJ
dpc-4454	3	89	ramified	ramified	ADJ
dpc-4454	3	90	plaques	plaque	NOUN
dpc-4454	3	91	in	in	ADP
dpc-4454	3	92	a	a	DET
dpc-4454	3	93	patient	patient	NOUN
dpc-4454	3	94	with	with	ADP
dpc-4454	3	95	multiple	multiple	ADJ
dpc-4454	3	96	myeloma	myeloma	NOUN
dpc-4454	3	97	.	.	PUNCT
dpc-4454	4	1	dermatol	dermatol	NOUN
dpc-4454	4	2	pract	pract	PROPN
dpc-4454	4	3	concept	concept	NOUN
dpc-4454	4	4	.	.	PUNCT
dpc-4454	5	1	2024;14(4):e2024243	2024;14(4):e2024243	X
dpc-4454	5	2	.	.	PUNCT
dpc-4454	6	1	doi	doi	PROPN
dpc-4454	6	2	:	:	PUNCT
dpc-4454	6	3	https://doi.org/10.5826/dpc.1404a243	https://doi.org/10.5826/dpc.1404a243	PROPN
dpc-4454	6	4	accepted	accept	VERB
dpc-4454	6	5	:	:	PUNCT
dpc-4454	6	6	june	june	PROPN
dpc-4454	6	7	5	5	NUM
dpc-4454	6	8	,	,	PUNCT
dpc-4454	6	9	2024	2024	NUM
dpc-4454	6	10	;	;	PUNCT
dpc-4454	6	11	published	publish	VERB
dpc-4454	6	12	:	:	PUNCT
dpc-4454	7	1	october	october	PROPN
dpc-4454	7	2	2024	2024	NUM
dpc-4454	7	3	copyright	copyright	NOUN
dpc-4454	7	4	:	:	PUNCT
dpc-4454	7	5	©	©	PROPN
dpc-4454	7	6	2024	2024	NUM
dpc-4454	7	7	güven	güven	PROPN
dpc-4454	7	8	et	et	PROPN
dpc-4454	7	9	al	al	PROPN
dpc-4454	7	10	.	.	PUNCT
dpc-4454	8	1	this	this	PRON
dpc-4454	8	2	is	be	AUX
dpc-4454	8	3	an	an	DET
dpc-4454	8	4	open	open	ADJ
dpc-4454	8	5	-	-	PUNCT
dpc-4454	8	6	access	access	NOUN
dpc-4454	8	7	article	article	NOUN
dpc-4454	8	8	distributed	distribute	VERB
dpc-4454	8	9	under	under	ADP
dpc-4454	8	10	the	the	DET
dpc-4454	8	11	terms	term	NOUN
dpc-4454	8	12	of	of	ADP
dpc-4454	8	13	the	the	DET
dpc-4454	8	14	creative	creative	ADJ
dpc-4454	8	15	commons	common	NOUN
dpc-4454	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4454	8	17	license	license	NOUN
dpc-4454	8	18	(	(	PUNCT
dpc-4454	8	19	by	by	ADP
dpc-4454	8	20	-	-	PUNCT
dpc-4454	8	21	nc-4.0	nc-4.0	NOUN
dpc-4454	8	22	)	)	PUNCT
dpc-4454	8	23	,	,	PUNCT
dpc-4454	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4454	8	25	,	,	PUNCT
dpc-4454	8	26	which	which	PRON
dpc-4454	8	27	permits	permit	VERB
dpc-4454	8	28	unrestricted	unrestricted	ADJ
dpc-4454	8	29	noncommercial	noncommercial	ADJ
dpc-4454	8	30	use	use	NOUN
dpc-4454	8	31	,	,	PUNCT
dpc-4454	8	32	distribution	distribution	NOUN
dpc-4454	8	33	,	,	PUNCT
dpc-4454	8	34	and	and	CCONJ
dpc-4454	8	35	reproduction	reproduction	NOUN
dpc-4454	8	36	in	in	ADP
dpc-4454	8	37	any	any	DET
dpc-4454	8	38	medium	medium	NOUN
dpc-4454	8	39	,	,	PUNCT
dpc-4454	8	40	provided	provide	VERB
dpc-4454	8	41	the	the	DET
dpc-4454	8	42	original	original	ADJ
dpc-4454	8	43	authors	author	NOUN
dpc-4454	8	44	and	and	CCONJ
dpc-4454	8	45	source	source	NOUN
dpc-4454	8	46	are	be	AUX
dpc-4454	8	47	credited	credit	VERB
dpc-4454	8	48	.	.	PUNCT
dpc-4454	9	1	funding	funding	NOUN
dpc-4454	9	2	:	:	PUNCT
dpc-4454	9	3	none	none	NOUN
dpc-4454	9	4	.	.	PUNCT
dpc-4454	10	1	competing	compete	VERB
dpc-4454	10	2	interests	interest	NOUN
dpc-4454	10	3	:	:	PUNCT
dpc-4454	10	4	none	none	NOUN
dpc-4454	10	5	.	.	PUNCT
dpc-4454	11	1	authorship	authorship	NOUN
dpc-4454	11	2	:	:	PUNCT
dpc-4454	11	3	all	all	DET
dpc-4454	11	4	authors	author	NOUN
dpc-4454	11	5	have	have	AUX
dpc-4454	11	6	contributed	contribute	VERB
dpc-4454	11	7	significantly	significantly	ADV
dpc-4454	11	8	to	to	ADP
dpc-4454	11	9	this	this	DET
dpc-4454	11	10	publication	publication	NOUN
dpc-4454	11	11	.	.	PUNCT
dpc-4454	12	1	corresponding	correspond	VERB
dpc-4454	12	2	author	author	NOUN
dpc-4454	12	3	:	:	PUNCT
dpc-4454	12	4	yusuf	yusuf	PROPN
dpc-4454	12	5	can	can	AUX
dpc-4454	12	6	edek	edek	VERB
dpc-4454	12	7	.	.	PUNCT
dpc-4454	13	1	address	address	NOUN
dpc-4454	13	2	:	:	PUNCT
dpc-4454	13	3	gazi	gazi	PROPN
dpc-4454	13	4	universitesi	universitesi	PROPN
dpc-4454	13	5	tip	tip	PROPN
dpc-4454	13	6	fakultesi	fakultesi	PROPN
dpc-4454	13	7	hastanesi	hastanesi	NOUN
dpc-4454	13	8	,	,	PUNCT
dpc-4454	13	9	emniyet	emniyet	NOUN
dpc-4454	13	10	mahallesi	mahallesi	NOUN
dpc-4454	13	11	,	,	PUNCT
dpc-4454	13	12	mevlana	mevlana	NOUN
dpc-4454	13	13	bulvari	bulvari	NOUN
dpc-4454	13	14	,	,	PUNCT
dpc-4454	13	15	no:29	no:29	PROPN
dpc-4454	13	16	,	,	PUNCT
dpc-4454	13	17	06560	06560	NUM
dpc-4454	13	18	ankara/	ankara/	NUM
dpc-4454	13	19	turkey	turkey	NOUN
dpc-4454	13	20	.	.	PUNCT
dpc-4454	14	1	telephone	telephone	NOUN
dpc-4454	14	2	number	number	NOUN
dpc-4454	14	3	:	:	PUNCT
dpc-4454	14	4	+903122026129	+903122026129	NUM
dpc-4454	14	5	/	/	SYM
dpc-4454	14	6	+905062818274	+905062818274	NUM
dpc-4454	14	7	e	e	NOUN
dpc-4454	14	8	-	-	NOUN
dpc-4454	14	9	mail	mail	NOUN
dpc-4454	14	10	:	:	PUNCT
dpc-4454	14	11	yusuf-can-35@hotmail.com	yusuf-can-35@hotmail.com	PROPN
dpc-4454	14	12	.	.	PUNCT
dpc-4454	14	13	introduction	introduction	NOUN
dpc-4454	14	14	herein	herein	NOUN
dpc-4454	14	15	,	,	PUNCT
dpc-4454	14	16	we	we	PRON
dpc-4454	14	17	present	present	VERB
dpc-4454	14	18	a	a	DET
dpc-4454	14	19	patient	patient	NOUN
dpc-4454	14	20	with	with	ADP
dpc-4454	14	21	multiple	multiple	ADJ
dpc-4454	14	22	myeloma	myeloma	NOUN
dpc-4454	14	23	who	who	PRON
dpc-4454	14	24	developed	develop	VERB
dpc-4454	14	25	erythematous	erythematous	ADJ
dpc-4454	14	26	and	and	CCONJ
dpc-4454	14	27	ramified	ramify	VERB
dpc-4454	14	28	skin	skin	NOUN
dpc-4454	14	29	lesions	lesion	NOUN
dpc-4454	14	30	after	after	ADP
dpc-4454	14	31	the	the	DET
dpc-4454	14	32	first	first	ADJ
dpc-4454	14	33	administration	administration	NOUN
dpc-4454	14	34	of	of	ADP
dpc-4454	14	35	bortezomib	bortezomib	NOUN
dpc-4454	14	36	subcutaneously	subcutaneously	ADV
dpc-4454	14	37	.	.	PUNCT
dpc-4454	15	1	case	case	NOUN
dpc-4454	15	2	presentation	presentation	NOUN
dpc-4454	15	3	a	a	DET
dpc-4454	15	4	34	34	NUM
dpc-4454	15	5	-	-	PUNCT
dpc-4454	15	6	year	year	NOUN
dpc-4454	15	7	-	-	PUNCT
dpc-4454	15	8	old	old	ADJ
dpc-4454	15	9	male	male	ADJ
dpc-4454	15	10	patient	patient	NOUN
dpc-4454	15	11	was	be	AUX
dpc-4454	15	12	admitted	admit	VERB
dpc-4454	15	13	to	to	ADP
dpc-4454	15	14	our	our	PRON
dpc-4454	15	15	dermatology	dermatology	NOUN
dpc-4454	15	16	outpatient	outpatient	NOUN
dpc-4454	15	17	clinic	clinic	NOUN
dpc-4454	15	18	with	with	ADP
dpc-4454	15	19	a	a	DET
dpc-4454	15	20	4	4	NUM
dpc-4454	15	21	-	-	PUNCT
dpc-4454	15	22	week	week	NOUN
dpc-4454	15	23	history	history	NOUN
dpc-4454	15	24	of	of	ADP
dpc-4454	15	25	an	an	DET
dpc-4454	15	26	asymptomatic	asymptomatic	ADJ
dpc-4454	15	27	erythematous	erythematous	ADJ
dpc-4454	15	28	rash	rash	NOUN
dpc-4454	15	29	on	on	ADP
dpc-4454	15	30	the	the	DET
dpc-4454	15	31	abdomen	abdoman	NOUN
dpc-4454	15	32	.	.	PUNCT
dpc-4454	16	1	the	the	DET
dpc-4454	16	2	patient	patient	NOUN
dpc-4454	16	3	was	be	AUX
dpc-4454	16	4	diagnosed	diagnose	VERB
dpc-4454	16	5	with	with	ADP
dpc-4454	16	6	igg	igg	PROPN
dpc-4454	16	7	kappa	kappa	PROPN
dpc-4454	16	8	multiple	multiple	PROPN
dpc-4454	16	9	myeloma	myeloma	PROPN
dpc-4454	16	10	three	three	NUM
dpc-4454	16	11	months	month	NOUN
dpc-4454	16	12	earlier	early	ADV
dpc-4454	16	13	by	by	ADP
dpc-4454	16	14	a	a	DET
dpc-4454	16	15	bone	bone	NOUN
dpc-4454	16	16	marrow	marrow	NOUN
dpc-4454	16	17	biopsy	biopsy	NOUN
dpc-4454	16	18	and	and	CCONJ
dpc-4454	16	19	initiated	initiate	VERB
dpc-4454	16	20	subcutaneous	subcutaneous	ADJ
dpc-4454	16	21	bortezomib	bortezomib	NOUN
dpc-4454	16	22	1.5	1.5	NUM
dpc-4454	16	23	mg	mg	PROPN
dpc-4454	16	24	/	/	SYM
dpc-4454	16	25	m2	m2	PROPN
dpc-4454	16	26	/	/	SYM
dpc-4454	16	27	week	week	NOUN
dpc-4454	16	28	,	,	PUNCT
dpc-4454	16	29	oral	oral	ADJ
dpc-4454	16	30	lenalidomide	lenalidomide	NOUN
dpc-4454	16	31	25	25	NUM
dpc-4454	16	32	mg	mg	NUM
dpc-4454	16	33	/	/	SYM
dpc-4454	16	34	day	day	NOUN
dpc-4454	16	35	,	,	PUNCT
dpc-4454	16	36	and	and	CCONJ
dpc-4454	16	37	intravenous	intravenous	ADJ
dpc-4454	16	38	dexamethasone	dexamethasone	NOUN
dpc-4454	16	39	20	20	NUM
dpc-4454	16	40	mg	mg	NUM
dpc-4454	16	41	/	/	SYM
dpc-4454	16	42	week	week	NOUN
dpc-4454	16	43	treatment	treatment	NOUN
dpc-4454	16	44	regimen	regiman	NOUN
dpc-4454	16	45	.	.	PUNCT
dpc-4454	17	1	the	the	DET
dpc-4454	17	2	patient	patient	NOUN
dpc-4454	17	3	stated	state	VERB
dpc-4454	17	4	that	that	SCONJ
dpc-4454	17	5	the	the	DET
dpc-4454	17	6	lesion	lesion	NOUN
dpc-4454	17	7	appeared	appear	VERB
dpc-4454	17	8	at	at	ADP
dpc-4454	17	9	the	the	DET
dpc-4454	17	10	bortezomib	bortezomib	NOUN
dpc-4454	17	11	injection	injection	NOUN
dpc-4454	17	12	site	site	NOUN
dpc-4454	17	13	after	after	ADP
dpc-4454	17	14	the	the	DET
dpc-4454	17	15	first	first	ADJ
dpc-4454	17	16	administration	administration	NOUN
dpc-4454	17	17	of	of	ADP
dpc-4454	17	18	the	the	DET
dpc-4454	17	19	drug	drug	NOUN
dpc-4454	17	20	and	and	CCONJ
dpc-4454	17	21	flared	flare	VERB
dpc-4454	17	22	up	up	ADP
dpc-4454	17	23	after	after	ADP
dpc-4454	17	24	the	the	DET
dpc-4454	17	25	second	second	ADJ
dpc-4454	17	26	administration	administration	NOUN
dpc-4454	17	27	.	.	PUNCT
dpc-4454	18	1	he	he	PRON
dpc-4454	18	2	denied	deny	VERB
dpc-4454	18	3	any	any	DET
dpc-4454	18	4	allergies	allergy	NOUN
dpc-4454	18	5	,	,	PUNCT
dpc-4454	18	6	trauma	trauma	NOUN
dpc-4454	18	7	,	,	PUNCT
dpc-4454	18	8	or	or	CCONJ
dpc-4454	18	9	infection	infection	NOUN
dpc-4454	18	10	.	.	PUNCT
dpc-4454	19	1	dermatological	dermatological	ADJ
dpc-4454	19	2	examination	examination	NOUN
dpc-4454	19	3	revealed	reveal	VERB
dpc-4454	19	4	erythematous	erythematous	ADJ
dpc-4454	19	5	plaques	plaque	NOUN
dpc-4454	19	6	which	which	PRON
dpc-4454	19	7	showed	show	VERB
dpc-4454	19	8	less	less	ADJ
dpc-4454	19	9	erythema	erythema	ADJ
dpc-4454	19	10	in	in	ADP
dpc-4454	19	11	the	the	DET
dpc-4454	19	12	central	central	ADJ
dpc-4454	19	13	parts	part	NOUN
dpc-4454	19	14	and	and	CCONJ
dpc-4454	19	15	ramified	ramified	ADJ
dpc-4454	19	16	extensions	extension	NOUN
dpc-4454	19	17	of	of	ADP
dpc-4454	19	18	erythema	erythema	ADV
dpc-4454	19	19	forming	form	VERB
dpc-4454	19	20	a	a	DET
dpc-4454	19	21	spider	spider	NOUN
dpc-4454	19	22	-	-	PUNCT
dpc-4454	19	23	like	like	ADJ
dpc-4454	19	24	lesion	lesion	NOUN
dpc-4454	19	25	on	on	ADP
dpc-4454	19	26	the	the	DET
dpc-4454	19	27	right	right	ADJ
dpc-4454	19	28	side	side	NOUN
dpc-4454	19	29	of	of	ADP
dpc-4454	19	30	the	the	DET
dpc-4454	19	31	abdomen	abdomen	NOUN
dpc-4454	19	32	(	(	PUNCT
dpc-4454	19	33	figure	figure	NOUN
dpc-4454	19	34	1a	1a	NOUN
dpc-4454	19	35	)	)	PUNCT
dpc-4454	19	36	.	.	PUNCT
dpc-4454	20	1	the	the	DET
dpc-4454	20	2	histopathological	histopathological	ADJ
dpc-4454	20	3	evaluation	evaluation	NOUN
dpc-4454	20	4	of	of	ADP
dpc-4454	20	5	the	the	DET
dpc-4454	20	6	specimen	speciman	NOUN
dpc-4454	20	7	,	,	PUNCT
dpc-4454	20	8	taken	take	VERB
dpc-4454	20	9	by	by	ADP
dpc-4454	20	10	a	a	DET
dpc-4454	20	11	punch	punch	NOUN
dpc-4454	20	12	biopsy	biopsy	NOUN
dpc-4454	20	13	from	from	ADP
dpc-4454	20	14	the	the	DET
dpc-4454	20	15	erythematous	erythematous	ADJ
dpc-4454	20	16	plaque	plaque	NOUN
dpc-4454	20	17	,	,	PUNCT
dpc-4454	20	18	showed	show	VERB
dpc-4454	20	19	mild	mild	ADJ
dpc-4454	20	20	intercellular	intercellular	ADJ
dpc-4454	20	21	edema	edema	NOUN
dpc-4454	20	22	in	in	ADP
dpc-4454	20	23	the	the	DET
dpc-4454	20	24	epidermis	epidermis	NOUN
dpc-4454	20	25	and	and	CCONJ
dpc-4454	20	26	perivascular	perivascular	ADJ
dpc-4454	20	27	mononuclear	mononuclear	ADJ
dpc-4454	20	28	inflammation	inflammation	NOUN
dpc-4454	20	29	accompanied	accompany	VERB
dpc-4454	20	30	by	by	ADP
dpc-4454	20	31	eosinophils	eosinophil	NOUN
dpc-4454	20	32	in	in	ADP
dpc-4454	20	33	the	the	DET
dpc-4454	20	34	superficial	superficial	ADJ
dpc-4454	20	35	dermis	dermis	NOUN
dpc-4454	20	36	(	(	PUNCT
dpc-4454	20	37	figure	figure	NOUN
dpc-4454	20	38	2	2	NUM
dpc-4454	20	39	)	)	PUNCT
dpc-4454	20	40	.	.	PUNCT
dpc-4454	21	1	thus	thus	ADV
dpc-4454	21	2	,	,	PUNCT
dpc-4454	21	3	the	the	DET
dpc-4454	21	4	diagnosis	diagnosis	NOUN
dpc-4454	21	5	of	of	ADP
dpc-4454	21	6	drug	drug	NOUN
dpc-4454	21	7	reaction	reaction	NOUN
dpc-4454	21	8	was	be	AUX
dpc-4454	21	9	made	make	VERB
dpc-4454	21	10	based	base	VERB
dpc-4454	21	11	on	on	ADP
dpc-4454	21	12	clinical	clinical	ADJ
dpc-4454	21	13	and	and	CCONJ
dpc-4454	21	14	histopathological	histopathological	ADJ
dpc-4454	21	15	findings	finding	NOUN
dpc-4454	21	16	.	.	PUNCT
dpc-4454	22	1	the	the	DET
dpc-4454	22	2	laboratory	laboratory	NOUN
dpc-4454	22	3	tests	test	NOUN
dpc-4454	22	4	(	(	PUNCT
dpc-4454	22	5	complete	complete	ADJ
dpc-4454	22	6	blood	blood	NOUN
dpc-4454	22	7	count	count	NOUN
dpc-4454	22	8	,	,	PUNCT
dpc-4454	22	9	biochemistry	biochemistry	NOUN
dpc-4454	22	10	panel	panel	NOUN
dpc-4454	22	11	,	,	PUNCT
dpc-4454	22	12	c	c	NOUN
dpc-4454	22	13	-	-	PUNCT
dpc-4454	22	14	reactive	reactive	ADJ
dpc-4454	22	15	protein	protein	NOUN
dpc-4454	22	16	,	,	PUNCT
dpc-4454	22	17	erythrocyte	erythrocyte	PROPN
dpc-4454	22	18	sedimentation	sedimentation	NOUN
dpc-4454	22	19	rate	rate	NOUN
dpc-4454	22	20	,	,	PUNCT
dpc-4454	22	21	and	and	CCONJ
dpc-4454	22	22	urine	urine	NOUN
dpc-4454	22	23	analysis	analysis	NOUN
dpc-4454	22	24	)	)	PUNCT
dpc-4454	22	25	were	be	AUX
dpc-4454	22	26	all	all	ADV
dpc-4454	22	27	within	within	ADP
dpc-4454	22	28	normal	normal	ADJ
dpc-4454	22	29	limits	limit	NOUN
dpc-4454	22	30	.	.	PUNCT
dpc-4454	23	1	bortezomib	bortezomib	PROPN
dpc-4454	23	2	treatment	treatment	NOUN
dpc-4454	23	3	was	be	AUX
dpc-4454	23	4	discontinued	discontinue	VERB
dpc-4454	23	5	,	,	PUNCT
dpc-4454	23	6	and	and	CCONJ
dpc-4454	23	7	the	the	DET
dpc-4454	23	8	lesion	lesion	NOUN
dpc-4454	23	9	regressed	regress	VERB
dpc-4454	23	10	after	after	ADP
dpc-4454	23	11	using	use	VERB
dpc-4454	23	12	mometasone	mometasone	NOUN
dpc-4454	23	13	furoate	furoate	NOUN
dpc-4454	23	14	0.1	0.1	NUM
dpc-4454	23	15	%	%	NOUN
dpc-4454	23	16	cream	cream	NOUN
dpc-4454	23	17	twice	twice	ADV
dpc-4454	23	18	daily	daily	ADV
dpc-4454	23	19	for	for	ADP
dpc-4454	23	20	two	two	NUM
dpc-4454	23	21	weeks	week	NOUN
dpc-4454	23	22	(	(	PUNCT
dpc-4454	23	23	figure	figure	NOUN
dpc-4454	23	24	1b	1b	NUM
dpc-4454	23	25	)	)	PUNCT
dpc-4454	23	26	.	.	PUNCT
dpc-4454	24	1	2	2	NUM
dpc-4454	24	2	research	research	NOUN
dpc-4454	24	3	letter	letter	NOUN
dpc-4454	24	4	|	|	ADV
dpc-4454	24	5	dermatol	dermatol	ADJ
dpc-4454	24	6	pract	pract	NOUN
dpc-4454	24	7	concept	concept	NOUN
dpc-4454	24	8	.	.	PUNCT
dpc-4454	25	1	2024;14(4):e2024243	2024;14(4):e2024243	NUM
dpc-4454	25	2	discussion	discussion	NOUN
dpc-4454	25	3	bortezomib	bortezomib	NOUN
dpc-4454	25	4	is	be	AUX
dpc-4454	25	5	a	a	DET
dpc-4454	25	6	reversible	reversible	ADJ
dpc-4454	25	7	proteasome	proteasome	NOUN
dpc-4454	25	8	inhibitor	inhibitor	NOUN
dpc-4454	25	9	used	use	VERB
dpc-4454	25	10	in	in	ADP
dpc-4454	25	11	the	the	DET
dpc-4454	25	12	treatment	treatment	NOUN
dpc-4454	25	13	of	of	ADP
dpc-4454	25	14	multiple	multiple	ADJ
dpc-4454	25	15	myeloma	myeloma	NOUN
dpc-4454	25	16	and	and	CCONJ
dpc-4454	25	17	lymphoma	lymphoma	NOUN
dpc-4454	25	18	.	.	PUNCT
dpc-4454	26	1	skin	skin	NOUN
dpc-4454	26	2	reactions	reaction	NOUN
dpc-4454	26	3	have	have	AUX
dpc-4454	26	4	been	be	AUX
dpc-4454	26	5	reported	report	VERB
dpc-4454	26	6	in	in	ADP
dpc-4454	26	7	up	up	ADP
dpc-4454	26	8	to	to	PART
dpc-4454	26	9	24	24	NUM
dpc-4454	26	10	%	%	NOUN
dpc-4454	26	11	of	of	ADP
dpc-4454	26	12	patients	patient	NOUN
dpc-4454	26	13	treated	treat	VERB
dpc-4454	26	14	with	with	ADP
dpc-4454	26	15	bortezomib	bortezomib	NOUN
dpc-4454	26	16	,	,	PUNCT
dpc-4454	26	17	usually	usually	ADV
dpc-4454	26	18	after	after	ADP
dpc-4454	26	19	the	the	DET
dpc-4454	26	20	third	third	ADJ
dpc-4454	26	21	or	or	CCONJ
dpc-4454	26	22	fourth	fourth	ADJ
dpc-4454	26	23	injection	injection	NOUN
dpc-4454	26	24	,	,	PUNCT
dpc-4454	26	25	and	and	CCONJ
dpc-4454	26	26	these	these	DET
dpc-4454	26	27	reactions	reaction	NOUN
dpc-4454	26	28	have	have	AUX
dpc-4454	26	29	been	be	AUX
dpc-4454	26	30	associated	associate	VERB
dpc-4454	26	31	with	with	ADP
dpc-4454	26	32	increased	increase	VERB
dpc-4454	26	33	pro	pro	ADJ
dpc-4454	26	34	inflammatory	inflammatory	ADJ
dpc-4454	26	35	cytokine	cytokine	ADJ
dpc-4454	26	36	production	production	NOUN
dpc-4454	27	1	[	[	X
dpc-4454	27	2	1	1	NUM
dpc-4454	27	3	]	]	PUNCT
dpc-4454	27	4	.	.	PUNCT
dpc-4454	28	1	dermatological	dermatological	ADJ
dpc-4454	28	2	side	side	NOUN
dpc-4454	28	3	effects	effect	NOUN
dpc-4454	28	4	of	of	ADP
dpc-4454	28	5	bortezomib	bortezomib	NOUN
dpc-4454	28	6	include	include	VERB
dpc-4454	28	7	injection	injection	NOUN
dpc-4454	28	8	site	site	NOUN
dpc-4454	28	9	reactions	reaction	NOUN
dpc-4454	28	10	,	,	PUNCT
dpc-4454	28	11	sweet	sweet	ADJ
dpc-4454	28	12	syndrome	syndrome	NOUN
dpc-4454	28	13	,	,	PUNCT
dpc-4454	28	14	maculopapular	maculopapular	ADJ
dpc-4454	28	15	eruption	eruption	NOUN
dpc-4454	28	16	,	,	PUNCT
dpc-4454	28	17	stevens	stevens	PROPN
dpc-4454	28	18	-	-	PUNCT
dpc-4454	28	19	johnson	johnson	PROPN
dpc-4454	28	20	syndrome	syndrome	NOUN
dpc-4454	28	21	,	,	PUNCT
dpc-4454	28	22	urticaria	urticaria	INTJ
dpc-4454	28	23	,	,	PUNCT
dpc-4454	28	24	cutaneous	cutaneous	ADJ
dpc-4454	28	25	vasculitis	vasculitis	NOUN
dpc-4454	28	26	,	,	PUNCT
dpc-4454	28	27	and	and	CCONJ
dpc-4454	28	28	neutrophilic	neutrophilic	ADJ
dpc-4454	28	29	dermatosis	dermatosis	NOUN
dpc-4454	29	1	[	[	X
dpc-4454	29	2	1	1	NUM
dpc-4454	29	3	-	-	SYM
dpc-4454	29	4	3	3	NUM
dpc-4454	29	5	]	]	PUNCT
dpc-4454	29	6	.	.	PUNCT
dpc-4454	30	1	however	however	ADV
dpc-4454	30	2	,	,	PUNCT
dpc-4454	30	3	bortezomib	bortezomib	NOUN
dpc-4454	30	4	-	-	PUNCT
dpc-4454	30	5	induced	induce	VERB
dpc-4454	30	6	skin	skin	NOUN
dpc-4454	30	7	reactions	reaction	NOUN
dpc-4454	30	8	usually	usually	ADV
dpc-4454	30	9	appear	appear	VERB
dpc-4454	30	10	as	as	ADP
dpc-4454	30	11	cutaneous	cutaneous	ADJ
dpc-4454	30	12	nodules	nodule	NOUN
dpc-4454	30	13	,	,	PUNCT
dpc-4454	30	14	plaques	plaque	NOUN
dpc-4454	30	15	,	,	PUNCT
dpc-4454	30	16	or	or	CCONJ
dpc-4454	30	17	morbilliform	morbilliform	NOUN
dpc-4454	30	18	erythema	erythema	ADJ
dpc-4454	30	19	.	.	PUNCT
dpc-4454	31	1	recently	recently	ADV
dpc-4454	31	2	,	,	PUNCT
dpc-4454	31	3	han	han	PROPN
dpc-4454	31	4	et	et	PROPN
dpc-4454	31	5	al	al	PROPN
dpc-4454	31	6	.	.	PROPN
dpc-4454	31	7	reported	report	VERB
dpc-4454	31	8	a	a	DET
dpc-4454	31	9	male	male	ADJ
dpc-4454	31	10	patient	patient	NOUN
dpc-4454	31	11	with	with	ADP
dpc-4454	31	12	multiple	multiple	ADJ
dpc-4454	31	13	myeloma	myeloma	NOUN
dpc-4454	31	14	who	who	PRON
dpc-4454	31	15	developed	develop	VERB
dpc-4454	31	16	bortezomib	bortezomib	NOUN
dpc-4454	31	17	-	-	PUNCT
dpc-4454	31	18	related	relate	VERB
dpc-4454	31	19	reticular	reticular	ADJ
dpc-4454	31	20	itchy	itchy	ADJ
dpc-4454	31	21	skin	skin	NOUN
dpc-4454	31	22	rash	rash	NOUN
dpc-4454	31	23	following	follow	VERB
dpc-4454	31	24	the	the	DET
dpc-4454	31	25	third	third	ADJ
dpc-4454	31	26	cycle	cycle	NOUN
dpc-4454	31	27	of	of	ADP
dpc-4454	31	28	the	the	DET
dpc-4454	31	29	treatment	treatment	NOUN
dpc-4454	31	30	[	[	X
dpc-4454	31	31	3	3	NUM
dpc-4454	31	32	]	]	PUNCT
dpc-4454	31	33	.	.	PUNCT
dpc-4454	32	1	moreover	moreover	ADV
dpc-4454	32	2	,	,	PUNCT
dpc-4454	32	3	a	a	DET
dpc-4454	32	4	similar	similar	ADJ
dpc-4454	32	5	case	case	NOUN
dpc-4454	32	6	with	with	ADP
dpc-4454	32	7	a	a	DET
dpc-4454	32	8	spider	spider	NOUN
dpc-4454	32	9	-	-	PUNCT
dpc-4454	32	10	like	like	ADJ
dpc-4454	32	11	erythematous	erythematous	ADJ
dpc-4454	32	12	lesion	lesion	NOUN
dpc-4454	32	13	following	follow	VERB
dpc-4454	32	14	bortezomib	bortezomib	NOUN
dpc-4454	32	15	treatment	treatment	NOUN
dpc-4454	32	16	was	be	AUX
dpc-4454	32	17	previously	previously	ADV
dpc-4454	32	18	described	describe	VERB
dpc-4454	32	19	[	[	PUNCT
dpc-4454	32	20	4	4	NUM
dpc-4454	32	21	]	]	PUNCT
dpc-4454	32	22	.	.	PUNCT
dpc-4454	33	1	furthermore	furthermore	ADV
dpc-4454	33	2	,	,	PUNCT
dpc-4454	33	3	plume	plume	NOUN
dpc-4454	33	4	et	et	PROPN
dpc-4454	33	5	al	al	PROPN
dpc-4454	33	6	.	.	PROPN
dpc-4454	33	7	reported	report	VERB
dpc-4454	33	8	spider	spider	NOUN
dpc-4454	33	9	-	-	PUNCT
dpc-4454	33	10	like	like	ADJ
dpc-4454	33	11	injection	injection	NOUN
dpc-4454	33	12	site	site	NOUN
dpc-4454	33	13	reactions	reaction	NOUN
dpc-4454	33	14	in	in	ADP
dpc-4454	33	15	three	three	NUM
dpc-4454	33	16	patients	patient	NOUN
dpc-4454	33	17	receiving	receive	VERB
dpc-4454	33	18	bortezomib	bortezomib	NOUN
dpc-4454	33	19	and	and	CCONJ
dpc-4454	33	20	two	two	NUM
dpc-4454	33	21	patients	patient	NOUN
dpc-4454	33	22	receiving	receive	VERB
dpc-4454	33	23	azacitidine	azacitidine	NOUN
dpc-4454	33	24	for	for	ADP
dpc-4454	33	25	the	the	DET
dpc-4454	33	26	treatment	treatment	NOUN
dpc-4454	33	27	of	of	ADP
dpc-4454	33	28	multiple	multiple	ADJ
dpc-4454	33	29	myeloma	myeloma	NOUN
dpc-4454	33	30	and	and	CCONJ
dpc-4454	33	31	myelodysplastic	myelodysplastic	ADJ
dpc-4454	33	32	syndrome	syndrome	NOUN
dpc-4454	34	1	[	[	X
dpc-4454	34	2	5	5	NUM
dpc-4454	34	3	]	]	PUNCT
dpc-4454	34	4	.	.	PUNCT
dpc-4454	35	1	conclusion	conclusion	NOUN
dpc-4454	35	2	we	we	PRON
dpc-4454	35	3	consider	consider	VERB
dpc-4454	35	4	that	that	SCONJ
dpc-4454	35	5	the	the	DET
dpc-4454	35	6	ramified	ramified	ADJ
dpc-4454	35	7	spider	spider	NOUN
dpc-4454	35	8	-	-	PUNCT
dpc-4454	35	9	like	like	ADJ
dpc-4454	35	10	skin	skin	NOUN
dpc-4454	35	11	eruption	eruption	NOUN
dpc-4454	35	12	developed	develop	VERB
dpc-4454	35	13	due	due	ADP
dpc-4454	35	14	to	to	ADP
dpc-4454	35	15	bortezomib	bortezomib	NOUN
dpc-4454	35	16	since	since	SCONJ
dpc-4454	35	17	the	the	DET
dpc-4454	35	18	lesion	lesion	NOUN
dpc-4454	35	19	appeared	appear	VERB
dpc-4454	35	20	at	at	ADP
dpc-4454	35	21	the	the	DET
dpc-4454	35	22	injection	injection	NOUN
dpc-4454	35	23	site	site	NOUN
dpc-4454	35	24	following	follow	VERB
dpc-4454	35	25	the	the	DET
dpc-4454	35	26	subcutaneous	subcutaneous	ADJ
dpc-4454	35	27	administration	administration	NOUN
dpc-4454	35	28	of	of	ADP
dpc-4454	35	29	the	the	DET
dpc-4454	35	30	drug	drug	NOUN
dpc-4454	35	31	.	.	PUNCT
dpc-4454	36	1	advances	advance	NOUN
dpc-4454	36	2	in	in	ADP
dpc-4454	36	3	cancer	cancer	NOUN
dpc-4454	36	4	treatment	treatment	NOUN
dpc-4454	36	5	and	and	CCONJ
dpc-4454	36	6	novel	novel	ADJ
dpc-4454	36	7	chemotherapy	chemotherapy	NOUN
dpc-4454	36	8	regimens	regimen	NOUN
dpc-4454	36	9	increase	increase	VERB
dpc-4454	36	10	the	the	DET
dpc-4454	36	11	risk	risk	NOUN
dpc-4454	36	12	of	of	ADP
dpc-4454	36	13	diverse	diverse	ADJ
dpc-4454	36	14	cutaneous	cutaneous	ADJ
dpc-4454	36	15	side	side	NOUN
dpc-4454	36	16	effects	effect	NOUN
dpc-4454	36	17	,	,	PUNCT
dpc-4454	36	18	leading	lead	VERB
dpc-4454	36	19	dermatologists	dermatologist	NOUN
dpc-4454	36	20	to	to	PART
dpc-4454	36	21	take	take	VERB
dpc-4454	36	22	an	an	DET
dpc-4454	36	23	important	important	ADJ
dpc-4454	36	24	role	role	NOUN
dpc-4454	36	25	in	in	ADP
dpc-4454	36	26	the	the	DET
dpc-4454	36	27	management	management	NOUN
dpc-4454	36	28	of	of	ADP
dpc-4454	36	29	patients	patient	NOUN
dpc-4454	36	30	with	with	ADP
dpc-4454	36	31	malignancies	malignancy	NOUN
dpc-4454	36	32	.	.	PUNCT
dpc-4454	37	1	establishing	establish	VERB
dpc-4454	37	2	the	the	DET
dpc-4454	37	3	cutaneous	cutaneous	ADJ
dpc-4454	37	4	side	side	NOUN
dpc-4454	37	5	effects	effect	NOUN
dpc-4454	37	6	of	of	ADP
dpc-4454	37	7	chemotherapy	chemotherapy	NOUN
dpc-4454	37	8	drugs	drug	NOUN
dpc-4454	37	9	may	may	AUX
dpc-4454	37	10	help	help	VERB
dpc-4454	37	11	to	to	PART
dpc-4454	37	12	take	take	VERB
dpc-4454	37	13	preventive	preventive	ADJ
dpc-4454	37	14	measures	measure	NOUN
dpc-4454	37	15	and	and	CCONJ
dpc-4454	37	16	to	to	PART
dpc-4454	37	17	initiate	initiate	VERB
dpc-4454	37	18	appropriate	appropriate	ADJ
dpc-4454	37	19	dermatological	dermatological	ADJ
dpc-4454	37	20	treatment	treatment	NOUN
dpc-4454	37	21	as	as	ADV
dpc-4454	37	22	early	early	ADV
dpc-4454	37	23	as	as	ADP
dpc-4454	37	24	possible	possible	ADJ
dpc-4454	37	25	to	to	PART
dpc-4454	37	26	prevent	prevent	VERB
dpc-4454	37	27	cessation	cessation	NOUN
dpc-4454	37	28	or	or	CCONJ
dpc-4454	37	29	delay	delay	NOUN
dpc-4454	37	30	of	of	ADP
dpc-4454	37	31	the	the	DET
dpc-4454	37	32	cancer	cancer	NOUN
dpc-4454	37	33	treatment	treatment	NOUN
dpc-4454	37	34	and	and	CCONJ
dpc-4454	37	35	improve	improve	VERB
dpc-4454	37	36	cancer	cancer	NOUN
dpc-4454	37	37	management	management	NOUN
dpc-4454	37	38	.	.	PUNCT
dpc-4454	38	1	our	our	PRON
dpc-4454	38	2	case	case	NOUN
dpc-4454	38	3	will	will	AUX
dpc-4454	38	4	hopefully	hopefully	ADV
dpc-4454	38	5	make	make	VERB
dpc-4454	38	6	a	a	DET
dpc-4454	38	7	significant	significant	ADJ
dpc-4454	38	8	contribution	contribution	NOUN
dpc-4454	38	9	to	to	ADP
dpc-4454	38	10	the	the	DET
dpc-4454	38	11	literature	literature	NOUN
dpc-4454	38	12	by	by	ADP
dpc-4454	38	13	describing	describe	VERB
dpc-4454	38	14	this	this	DET
dpc-4454	38	15	rare	rare	ADJ
dpc-4454	38	16	cutaneous	cutaneous	ADJ
dpc-4454	38	17	side	side	ADJ
dpc-4454	38	18	effect	effect	NOUN
dpc-4454	38	19	of	of	ADP
dpc-4454	38	20	bortezomib	bortezomib	NOUN
dpc-4454	38	21	and	and	CCONJ
dpc-4454	38	22	determining	determine	VERB
dpc-4454	38	23	its	its	PRON
dpc-4454	38	24	clinical	clinical	ADJ
dpc-4454	38	25	features	feature	NOUN
dpc-4454	38	26	.	.	PUNCT
dpc-4454	39	1	references	reference	NOUN
dpc-4454	39	2	1	1	NUM
dpc-4454	39	3	.	.	PUNCT
dpc-4454	39	4	reyes	reyes	PROPN
dpc-4454	39	5	-	-	PUNCT
dpc-4454	39	6	habito	habito	PROPN
dpc-4454	39	7	cm	cm	PROPN
dpc-4454	39	8	,	,	PUNCT
dpc-4454	39	9	roh	roh	PROPN
dpc-4454	39	10	ek	ek	PROPN
dpc-4454	39	11	.	.	PROPN
dpc-4454	39	12	cutaneous	cutaneous	ADJ
dpc-4454	39	13	reactions	reaction	NOUN
dpc-4454	39	14	to	to	ADP
dpc-4454	39	15	chemotherapeutic	chemotherapeutic	ADJ
dpc-4454	39	16	drugs	drug	NOUN
dpc-4454	39	17	and	and	CCONJ
dpc-4454	39	18	targeted	target	VERB
dpc-4454	39	19	therapies	therapy	NOUN
dpc-4454	39	20	for	for	ADP
dpc-4454	39	21	cancer	cancer	NOUN
dpc-4454	39	22	:	:	PUNCT
dpc-4454	39	23	part	part	NOUN
dpc-4454	39	24	i.	i.	PROPN
dpc-4454	39	25	conventional	conventional	ADJ
dpc-4454	39	26	chemotherapeutic	chemotherapeutic	ADJ
dpc-4454	39	27	drugs	drug	NOUN
dpc-4454	39	28	.	.	PUNCT
dpc-4454	40	1	j	j	PROPN
dpc-4454	40	2	am	be	AUX
dpc-4454	40	3	acad	acad	ADJ
dpc-4454	40	4	dermatol	dermatol	NOUN
dpc-4454	40	5	.	.	PUNCT
dpc-4454	41	1	2014	2014	NUM
dpc-4454	41	2	aug;71(2):203.e1	aug;71(2):203.e1	PROPN
dpc-4454	41	3	-	-	PUNCT
dpc-4454	41	4	203.e12	203.e12	PROPN
dpc-4454	41	5	.	.	PUNCT
dpc-4454	42	1	doi	doi	NOUN
dpc-4454	42	2	:	:	PUNCT
dpc-4454	42	3	10.1016	10.1016	NUM
dpc-4454	42	4	/	/	SYM
dpc-4454	42	5	j.jaad.2014.04.014	j.jaad.2014.04.014	PROPN
dpc-4454	42	6	.	.	PROPN
dpc-4454	43	1	2	2	X
dpc-4454	43	2	.	.	X
dpc-4454	43	3	han	han	PROPN
dpc-4454	43	4	j	j	PROPN
dpc-4454	43	5	,	,	PUNCT
dpc-4454	43	6	owji	owji	PROPN
dpc-4454	43	7	s	s	PROPN
dpc-4454	43	8	,	,	PUNCT
dpc-4454	43	9	agarwal	agarwal	PROPN
dpc-4454	43	10	a	a	X
dpc-4454	43	11	,	,	PUNCT
dpc-4454	43	12	et	et	PROPN
dpc-4454	43	13	al	al	PROPN
dpc-4454	43	14	.	.	PROPN
dpc-4454	43	15	bortezomib	bortezomib	NOUN
dpc-4454	43	16	-	-	PUNCT
dpc-4454	43	17	induced	induce	VERB
dpc-4454	43	18	reticular	reticular	ADJ
dpc-4454	43	19	eruption	eruption	NOUN
dpc-4454	43	20	in	in	ADP
dpc-4454	43	21	patient	patient	NOUN
dpc-4454	43	22	with	with	ADP
dpc-4454	43	23	multiple	multiple	ADJ
dpc-4454	43	24	myeloma	myeloma	NOUN
dpc-4454	43	25	.	.	PUNCT
dpc-4454	44	1	dermatopathology	dermatopathology	NOUN
dpc-4454	44	2	(	(	PUNCT
dpc-4454	44	3	basel	basel	PROPN
dpc-4454	44	4	)	)	PUNCT
dpc-4454	44	5	.	.	PUNCT
dpc-4454	45	1	2023	2023	NUM
dpc-4454	45	2	jul	jul	PROPN
dpc-4454	45	3	21;10(3):226	21;10(3):226	NUM
dpc-4454	45	4	-	-	SYM
dpc-4454	45	5	230	230	NUM
dpc-4454	45	6	.	.	PUNCT
dpc-4454	46	1	doi	doi	NOUN
dpc-4454	46	2	:	:	PUNCT
dpc-4454	46	3	10.3390	10.3390	NUM
dpc-4454	46	4	/dermatopathology10030031	/dermatopathology10030031	PUNCT
dpc-4454	46	5	.	.	PUNCT
dpc-4454	47	1	figure	figure	NOUN
dpc-4454	47	2	1	1	NUM
dpc-4454	47	3	(	(	PUNCT
dpc-4454	47	4	a	a	NOUN
dpc-4454	47	5	)	)	PUNCT
dpc-4454	47	6	erythematous	erythematous	ADJ
dpc-4454	47	7	plaques	plaque	NOUN
dpc-4454	47	8	with	with	ADP
dpc-4454	47	9	less	less	ADJ
dpc-4454	47	10	erythema	erythema	ADJ
dpc-4454	47	11	in	in	ADP
dpc-4454	47	12	the	the	DET
dpc-4454	47	13	central	central	ADJ
dpc-4454	47	14	parts	part	NOUN
dpc-4454	47	15	accompanied	accompany	VERB
dpc-4454	47	16	by	by	ADP
dpc-4454	47	17	ramified	ramify	VERB
dpc-4454	47	18	spider	spider	NOUN
dpc-4454	47	19	-	-	PUNCT
dpc-4454	47	20	like	like	ADJ
dpc-4454	47	21	extensions	extension	NOUN
dpc-4454	47	22	on	on	ADP
dpc-4454	47	23	the	the	DET
dpc-4454	47	24	right	right	ADJ
dpc-4454	47	25	abdomen	abdomen	NOUN
dpc-4454	47	26	.	.	PUNCT
dpc-4454	48	1	(	(	PUNCT
dpc-4454	48	2	b	b	X
dpc-4454	48	3	)	)	PUNCT
dpc-4454	48	4	the	the	DET
dpc-4454	48	5	lesion	lesion	NOUN
dpc-4454	48	6	healed	heal	VERB
dpc-4454	48	7	four	four	NUM
dpc-4454	48	8	weeks	week	NOUN
dpc-4454	48	9	after	after	ADP
dpc-4454	48	10	treatment	treatment	NOUN
dpc-4454	48	11	,	,	PUNCT
dpc-4454	48	12	leaving	leave	VERB
dpc-4454	48	13	post	post	ADJ
dpc-4454	48	14	-	-	ADJ
dpc-4454	48	15	inflammatory	inflammatory	ADJ
dpc-4454	48	16	hyperpigmentation	hyperpigmentation	NOUN
dpc-4454	48	17	.	.	PUNCT
dpc-4454	49	1	figure	figure	NOUN
dpc-4454	49	2	2	2	NUM
dpc-4454	49	3	(	(	PUNCT
dpc-4454	49	4	a	a	DET
dpc-4454	49	5	)	)	PUNCT
dpc-4454	49	6	mild	mild	ADJ
dpc-4454	49	7	intercellular	intercellular	ADJ
dpc-4454	49	8	edema	edema	NOUN
dpc-4454	49	9	in	in	ADP
dpc-4454	49	10	the	the	DET
dpc-4454	49	11	epidermis	epidermis	NOUN
dpc-4454	49	12	and	and	CCONJ
dpc-4454	49	13	perivascular	perivascular	ADJ
dpc-4454	49	14	mononuclear	mononuclear	ADJ
dpc-4454	49	15	inflammation	inflammation	NOUN
dpc-4454	49	16	accompanied	accompany	VERB
dpc-4454	49	17	by	by	ADP
dpc-4454	49	18	eosinophils	eosinophil	NOUN
dpc-4454	49	19	in	in	ADP
dpc-4454	49	20	the	the	DET
dpc-4454	49	21	superficial	superficial	ADJ
dpc-4454	49	22	dermis	dermis	NOUN
dpc-4454	49	23	(	(	PUNCT
dpc-4454	49	24	h&e	h&e	PROPN
dpc-4454	49	25	,	,	PUNCT
dpc-4454	49	26	×20	×20	PROPN
dpc-4454	49	27	)	)	PUNCT
dpc-4454	49	28	.	.	PUNCT
dpc-4454	50	1	(	(	PUNCT
dpc-4454	50	2	b	b	X
dpc-4454	50	3	)	)	PUNCT
dpc-4454	50	4	close	close	ADJ
dpc-4454	50	5	view	view	NOUN
dpc-4454	50	6	of	of	ADP
dpc-4454	50	7	the	the	DET
dpc-4454	50	8	eosinophils	eosinophil	NOUN
dpc-4454	50	9	(	(	PUNCT
dpc-4454	50	10	h&e	h&e	NOUN
dpc-4454	50	11	,	,	PUNCT
dpc-4454	50	12	×400	×400	PROPN
dpc-4454	50	13	)	)	PUNCT
dpc-4454	50	14	.	.	PUNCT
dpc-4454	51	1	research	research	NOUN
dpc-4454	51	2	letter	letter	NOUN
dpc-4454	51	3	|	|	ADV
dpc-4454	51	4	dermatol	dermatol	ADJ
dpc-4454	51	5	pract	pract	NOUN
dpc-4454	51	6	concept	concept	NOUN
dpc-4454	51	7	.	.	PUNCT
dpc-4454	52	1	2024;14(4):e2024243	2024;14(4):e2024243	NUM
dpc-4454	52	2	3	3	NUM
dpc-4454	52	3	3	3	NUM
dpc-4454	52	4	.	.	PUNCT
dpc-4454	52	5	choi	choi	PROPN
dpc-4454	52	6	gs	gs	PROPN
dpc-4454	52	7	,	,	PUNCT
dpc-4454	52	8	lee	lee	PROPN
dpc-4454	52	9	hs	hs	PROPN
dpc-4454	52	10	,	,	PUNCT
dpc-4454	52	11	kim	kim	PROPN
dpc-4454	52	12	hk	hk	PROPN
dpc-4454	52	13	.	.	PUNCT
dpc-4454	53	1	a	a	DET
dpc-4454	53	2	case	case	NOUN
dpc-4454	53	3	of	of	ADP
dpc-4454	53	4	bortezomib	bortezomib	NOUN
dpc-4454	53	5	(	(	PUNCT
dpc-4454	53	6	velcade	velcade	PROPN
dpc-4454	53	7	)	)	PUNCT
dpc-4454	53	8	induced	induce	VERB
dpc-4454	53	9	stevens	stevens	PROPN
dpc-4454	53	10	-	-	PUNCT
dpc-4454	53	11	johnson	johnson	PROPN
dpc-4454	53	12	syndrome	syndrome	PROPN
dpc-4454	53	13	confirmed	confirm	VERB
dpc-4454	53	14	by	by	ADP
dpc-4454	53	15	patch	patch	PROPN
dpc-4454	53	16	test	test	NOUN
dpc-4454	53	17	.	.	PUNCT
dpc-4454	54	1	asia	asia	PROPN
dpc-4454	54	2	pac	pac	PROPN
dpc-4454	54	3	allergy	allergy	PROPN
dpc-4454	54	4	.	.	PUNCT
dpc-4454	55	1	2021	2021	NUM
dpc-4454	55	2	apr	apr	PROPN
dpc-4454	55	3	21;11(2):e17	21;11(2):e17	NUM
dpc-4454	55	4	.	.	PUNCT
dpc-4454	56	1	doi	doi	NOUN
dpc-4454	56	2	:	:	PUNCT
dpc-4454	56	3	10.5415	10.5415	NUM
dpc-4454	56	4	/	/	SYM
dpc-4454	56	5	apallergy	apallergy	NOUN
dpc-4454	56	6	.2021.11.e17	.2021.11.e17	PUNCT
dpc-4454	56	7	.	.	PROPN
dpc-4454	57	1	4	4	NUM
dpc-4454	57	2	.	.	X
dpc-4454	57	3	kurtin	kurtin	PROPN
dpc-4454	57	4	s	s	PROPN
dpc-4454	57	5	,	,	PUNCT
dpc-4454	57	6	knop	knop	PROPN
dpc-4454	57	7	cs	cs	PROPN
dpc-4454	57	8	,	,	PUNCT
dpc-4454	57	9	milliron	milliron	ADJ
dpc-4454	57	10	t.	t.	ADJ
dpc-4454	57	11	subcutaneous	subcutaneous	ADJ
dpc-4454	57	12	administration	administration	NOUN
dpc-4454	57	13	of	of	ADP
dpc-4454	57	14	bortezomib	bortezomib	PROPN
dpc-4454	57	15	:	:	PUNCT
dpc-4454	57	16	strategies	strategy	NOUN
dpc-4454	57	17	to	to	PART
dpc-4454	57	18	reduce	reduce	VERB
dpc-4454	57	19	injection	injection	NOUN
dpc-4454	57	20	site	site	NOUN
dpc-4454	57	21	reactions	reaction	NOUN
dpc-4454	57	22	.	.	PUNCT
dpc-4454	58	1	j	j	PROPN
dpc-4454	58	2	adv	adv	PROPN
dpc-4454	58	3	pract	pract	PROPN
dpc-4454	58	4	oncol	oncol	PROPN
dpc-4454	58	5	.	.	PUNCT
dpc-4454	59	1	2012	2012	NUM
dpc-4454	59	2	nov;3(6):406	nov;3(6):406	VERB
dpc-4454	59	3	-	-	SYM
dpc-4454	59	4	10	10	NUM
dpc-4454	59	5	.	.	PUNCT
dpc-4454	60	1	doi	doi	NOUN
dpc-4454	60	2	:	:	PUNCT
dpc-4454	60	3	10.6004	10.6004	NUM
dpc-4454	60	4	/	/	SYM
dpc-4454	60	5	jadpro	jadpro	ADJ
dpc-4454	60	6	.2012.3.6.8	.2012.3.6.8	X
dpc-4454	60	7	.	.	PUNCT
dpc-4454	61	1	5	5	X
dpc-4454	61	2	.	.	X
dpc-4454	61	3	plume	plume	PROPN
dpc-4454	61	4	ma	ma	PROPN
dpc-4454	61	5	,	,	PUNCT
dpc-4454	61	6	sibaud	sibaud	NOUN
dpc-4454	61	7	v	v	NOUN
dpc-4454	61	8	,	,	PUNCT
dpc-4454	61	9	bobin	bobin	NOUN
dpc-4454	61	10	a	a	NOUN
dpc-4454	61	11	,	,	PUNCT
dpc-4454	61	12	et	et	PROPN
dpc-4454	61	13	al	al	PROPN
dpc-4454	61	14	.	.	PUNCT
dpc-4454	61	15	spider	spider	NOUN
dpc-4454	61	16	-	-	PUNCT
dpc-4454	61	17	like	like	ADJ
dpc-4454	61	18	injection	injection	NOUN
dpc-4454	61	19	site	site	NOUN
dpc-4454	61	20	reaction	reaction	NOUN
dpc-4454	61	21	after	after	ADP
dpc-4454	61	22	subcutaneous	subcutaneous	ADJ
dpc-4454	61	23	administration	administration	NOUN
dpc-4454	61	24	of	of	ADP
dpc-4454	61	25	haematological	haematological	ADJ
dpc-4454	61	26	treatments	treatment	NOUN
dpc-4454	61	27	.	.	PUNCT
dpc-4454	62	1	j	j	PROPN
dpc-4454	62	2	eur	eur	PROPN
dpc-4454	62	3	acad	acad	PROPN
dpc-4454	62	4	dermatol	dermatol	NOUN
dpc-4454	62	5	venereol	venereol	NOUN
dpc-4454	62	6	.	.	PUNCT
dpc-4454	63	1	2020	2020	NUM
dpc-4454	63	2	mar;34(3	mar;34(3	NOUN
dpc-4454	63	3	):	):	PUNCT
dpc-4454	63	4	e142	e142	PROPN
dpc-4454	63	5	-	-	PUNCT
dpc-4454	63	6	e144	e144	PROPN
dpc-4454	63	7	.	.	PUNCT
dpc-4454	63	8	doi	doi	PROPN
dpc-4454	63	9	:	:	PUNCT
dpc-4454	63	10	10.1111	10.1111	NUM
dpc-4454	63	11	/	/	SYM
dpc-4454	63	12	jdv.16049	jdv.16049	PROPN
dpc-4454	63	13	.	.	PUNCT